Nxera Pharma (SOLTF) Stock Price, News & Analysis

Company Overview

Nxera Pharma Co., Ltd., formerly known as Sosei Group Corporation and Sosei Heptares, is a biopharmaceutical company focused on discovering and developing medicines that target G protein-coupled receptors (GPCRs). These receptors are involved in a wide range of biological processes and represent an important class of targets for treatments in areas including neuroscience, immunology, inflammation, metabolic disease and other therapeutic fields.

The company combines structure-based drug design, computational chemistry and its proprietary StaR technology to identify and optimize drug candidates. Nxera develops selected programs internally and works with pharmaceutical and biotechnology partners through research collaborations, licensing arrangements and co-development agreements. Its activities include early-stage discovery, preclinical research and clinical development of small-molecule and other targeted therapies.

Nxera has historical roots in Japan and the United Kingdom, where Sosei established a significant research presence through its acquisition of Heptares Therapeutics. The company serves the international pharmaceutical market through global partnerships and research operations in Japan, the United Kingdom and other locations. In 2023, Sosei Group adopted the Nxera Pharma name as part of a broader effort to present its business as a global, technology-driven drug discovery company.

Key Stats

• Today's Range: $8.43 to $8.43
• 50-Day Range: $5.01 to $8.43
• 52-Week Range: $4.90 to $8.43
• Volume: N/A
• Average Volume: 2,379 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/24/2026
• Next Earnings (Estimated): 10/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:SOLTF
• CIK: N/A
• Web: www.nxera.life
• Phone: (135) 210-3290
• Fax: N/A
• Employees: 382
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A